Recent advances in idiopathic pulmonary fibrosis

Tuberculosis and Respiratory Diseases

Volumn 74, Issue 1, 2013, Pages 1-6

  Park, Sanghoon ^a   Lee, Eun Joo ^b  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Clinical trial; Etiology; Idiopathic pulmonary fibrosis

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; BOSENTAN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; LOSARTAN; MATRILYSIN; NEUTROPHIL COLLAGENASE; NINTEDANIB; PIRFENIDONE; PLACEBO; PREDNISONE; THALIDOMIDE; WARFARIN;

AGING; AIRWAY REMODELING; AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; CELL DIFFERENTIATION; COUGHING; DRUG EFFICACY; DRUG WITHDRAWAL; EXPLORATORY RESEARCH; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; LUNG ALVEOLUS CELL TYPE 1; LUNG ALVEOLUS EPITHELIUM; LUNG INJURY; MESOTHELIUM CELL; MONOTHERAPY; MYOFIBROBLAST; PERICYTE; PHASE 3 CLINICAL TRIAL (TOPIC); PILOT STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TREATMENT WITHDRAWAL;

EID: 84874475811     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2013.74.1.1     Document Type: Review

References (14)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378:1949-61.
3. Ding Q, Luckhardt T, Hecker L, Zhou Y, Liu G, Antony VB, et al. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. Drugs 2011;71:981-1001.
4. Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 2012;380:680-8.
5. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-77.
6. Homma S, Azuma A, Taniguchi H, Ogura T, Mochiduki Y, Sugiyama Y, et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology 2012;17:467-77.
7. Horton MR, Santopietro V, Mathew L, Horton KM, Polito AJ, Liu MC, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis:, a randomized trial. Ann Intern Med 2012;157:398-406.
8. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;186:88-95.
9. King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:92-9.
10. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9.
11. Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, Kondoh Y, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011;12:143.
12. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-87.
13. Couluris M, Kinder BW, Xu P, Gross-King M, Krischer J, Panos RJ. Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project. Lung 2012;190:523-7.
14. Tzouvelekis A, Koliakos G, Ntolios P, Baira I, Bouros E, Oikonomou A, et al. Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal. J Transl Med 2011;9:182.